Neupro Patch, Extended Release
Product Images NDC 50474-802

Product Visual Gallery

This gallery contains 32 technical images submitted to the FDA as part of the official labeling for Neupro (NDC 50474-802). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ucb, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Neupro 01)

Chemical structure of rotigotine, the active ingredient in Neupro, displayed as a 2D molecular diagram showing its functional groups and ring structures.*

FDA Label Image

Figure (Neupro 02)

Neupro (rotigotine) transdermal patch, extended release. The image shows a rectangular patch with a light orange upper section and a larger white lower section, indicating the adhesive transdermal delivery form. The patch is designed for continuous drug release over 24 hours. Labeler: UCB, Inc.*

FDA Label Image

Figure 1 (Neupro 03)

A line graph depicting rotigotine plasma concentration (ng/mL) over 24 hours after transdermal administration of Neupro patch at days 27 and 30. The x-axis shows time in hours, and the y-axis shows rotigotine levels ranging from 0 to 1.6 ng/mL, including error bars indicating variability. Two lines represent concentrations on day 27 and day 30, showing similar pharmacokinetic profiles over time.*

FDA Label Image

Figure A (Neupro 04)

An instructional illustration showing hands holding a Neupro patch package. The package is labeled with Neupro brand name and contains detailed text instructions or information about the rotigotine extended-release transdermal patch.*

FDA Label Image

Figure B (Neupro 05)

An illustration showing recommended application sites for Neupro (rotigotine) transdermal patch on the human body. Highlighted areas include the shoulders, upper arms, abdomen, hips, and upper back from front, side, and back views.*

FDA Label Image

Figure C (Neupro 06)

An instructional illustration showing hands peeling apart a folded backing liner, demonstrating the step to remove the patch from its protective covering.*

FDA Label Image

Figure D (Neupro 07)

Illustration showing hands holding a booklet or leaflet with a single rectangular patch adhered on the right inside page, likely demonstrating the Neupro rotigotine transdermal patch in its unopened or partially opened packaging.*

FDA Label Image

Figure E (Neupro 08)

An instructional illustration showing two hands opening a booklet or packet containing a transdermal patch. One hand holds the booklet, and the other hand peels back the layer to reveal the patch inside, demonstrating proper handling or application technique.*

FDA Label Image

Figure F (Neupro 09)

An instructional illustration showing two hands peeling the backing from a square transdermal patch. The image likely demonstrates the preparation step for applying the Neupro (rotigotine) extended-release transdermal patch.*

FDA Label Image

Figure G (Neupro 10)

An instructional illustration showing hands peeling apart a backing to reveal a Neupro (rotigotine) transdermal patch. The image demonstrates how to properly handle and prepare the extended-release patch for application.*

FDA Label Image

Figure H (Neupro 11)

An instructional line drawing showing two hands peeling the backing off a Neupro transdermal patch. One hand holds the patch while the other hand peels away the protective liner, demonstrating the proper method of application for this extended-release rotigotine patch.*

FDA Label Image

Figure I (Neupro 12)

An instructional illustration showing a person applying a Neupro transdermal patch to the inner forearm. The patch is rectangular and light brown, positioned on the skin with one hand pressing it into place.*

FDA Label Image

Figure J (Neupro 13)

An instructional illustration showing a person applying a rectangular transdermal patch to the skin on the inner forearm. The hand is pressing the patch onto the skin to ensure proper adhesion, demonstrating application technique for a medication patch.*

FDA Label Image

Figure K (Neupro 14)

An instructional illustration showing a person applying a transdermal patch to the inner upper arm. The image includes a timer set for 30 seconds, indicating the recommended duration for holding the patch on the skin for proper adhesion.*

FDA Label Image

Principal Display Panel (1 mg Pouch Carton)

An instructional line drawing showing a person holding a Neupro (rotigotine) transdermal patch package with both hands, demonstrating proper handling before application.*

FDA Label Image

Principal Display Panel (2 mg Pouch Carton)

Illustration showing recommended application sites for the Neupro (rotigotine) transdermal patch. The highlighted areas on the front, side, and back views of a human figure indicate suitable locations for patch placement, including the upper arms, shoulders, upper back, abdomen, and thighs.*

FDA Label Image

Principal Display Panel (3 mg Pouch Carton)

An instructional illustration showing two hands peeling apart the backing from a rectangular transdermal patch, indicating the steps for removing the protective layer prior to application.*

FDA Label Image

Principal Display Panel (4 mg Pouch Carton)

An instructional illustration showing two hands opening a packet or pouch containing a Neupro transdermal patch. The patch is visible inside the packaging, demonstrating how to access the extended-release rotigotine patch for application.*

FDA Label Image

Principal Display Panel (6 mg Pouch Carton)

An instructional illustration depicting hands peeling a Neupro patch from its backing within a paper leaflets or folding guide. The image shows the correct technique for removing the transdermal patch from the protective liner before application to the skin.*

FDA Label Image

Principal Display Panel (8 mg Pouch Carton)

An illustration showing two hands handling a Neupro rotigotine patch, extended-release transdermal dosage form. The image demonstrates holding and peeling the patch from its backing prior to application on the skin.*

FDA Label Image

Principal Display Panel (Kit Carton)

An instructional line drawing showing two hands peeling apart a Neupro transdermal patch's backing to prepare for application. The image illustrates how to remove the protective liner from the patch, which is a rotigotine extended-release patch used for delivering medication through the skin.*

FDA Label Image

Neupro 22

An instructional line drawing showing hands peeling off the backing from a Neupro patch, illustrating part of the application process for this transdermal extended-release rotigotine patch.*

FDA Label Image

Neupro 23

An instructional illustration showing the application of the Neupro (rotigotine) transdermal patch to the inner forearm. The image depicts a hand pressing the patch onto the skin, highlighting the method of use for this extended-release delivery system.*

FDA Label Image

Neupro 24

An instructional illustration showing a hand applying a rectangular transdermal patch to the inside of a forearm. The patch appears to be a rotigotine extended-release patch, consistent with the Neupro product usage instructions.*

FDA Label Image

Neupro 25

Instructional illustration demonstrating the application of a Neupro patch. The image shows a hand placing the patch on the inner forearm with a timer displaying 30 seconds, indicating the recommended time to press the patch firmly to the skin for proper adhesion.*

FDA Label Image

Neupro 26

Flat packaging label for Neupro 1 mg/24 hours patch, a rotigotine transdermal system. The label shows the product name, strength, dosage form, and route. It is labeled for transdermal use only and prescription use (Rx only). The labeler is UCB, Inc., with manufacturing in Germany. The package is for 30 systems and includes regulatory and barcode details.*

FDA Label Image

Neupro 27

Flat packaging label for Neupro 2 mg/24 hours rotigotine transdermal system patch. The label displays the proprietary name Neupro and generic name rotigotine transdermal system in blue text with the strength 2 mg/24 hours in orange. It indicates the product is for transdermal use only and is Rx only. The labeler is UCB, Inc. with manufacturing origin noted as Made in Germany. The package size is 30 systems and includes barcode and regulatory information.*

FDA Label Image

Neupro 28

Neupro 3 mg/24 hours rotigotine transdermal system carton for 30 systems. The packaging features the product name, strength, and dosage form, emphasizing its use as a transdermal patch. It is manufactured for UCB, Inc., Smyrna, GA, and includes trademark and manufacturing details. The label also states "For transdermal use only" and "Rx Only."*

FDA Label Image

Neupro 29

Packaging label for Neupro 4 mg/24 hours rotigotine transdermal system patch. The label shows the product name, active ingredient, and strength prominently in blue and red text. It indicates transdermal use only and prescription status. The label includes manufacturer information: UCB, Inc., Smyrna, GA, Made in Germany, and shows a package size of 30 systems.*

FDA Label Image

Neupro 30

Neupro 6 mg/24 hours (rotigotine transdermal system) packaging label for a 30-system carton. The label features the brand name Neupro and generic name rotigotine transdermal system prominently, with dosage strength in green text. It indicates transdermal use only, Rx only status, and includes manufacturer details for UCB, Inc., Smyrna, GA, with product made in Germany. Warnings and handling instructions are also visible on the label.*

FDA Label Image

Neupro 31

Neupro 8 mg/24 hours (rotigotine transdermal system) packaging label. The label shows the proprietary and generic names, dosage strength and form as a transdermal patch system delivering 8 mg over 24 hours. Labeler is UCB, Inc., with manufacturing information indicating it is made in Germany. The package contains 30 systems and includes warnings and storage instructions printed on the label.*

FDA Label Image

Neupro 32

Neupro (rotigotine transdermal system) titration kit carton label for Parkinson’s disease treatment. The packaging includes 7 systems delivering 2 mg/24 hours and 7 systems delivering 4 mg/24 hours. The label highlights step-by-step therapy guidance, safety information, and contains instructions for weekly use of the 2 mg and 4 mg patches. Manufactured by UCB, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.